Surviving the nasty surprise of investigator fraud in the US
This article was originally published in SRA
Executive Summary
Fraudulent behaviour by clinical investigators can sink a trial and, if only caught post-launch, savage market confidence in a new drug. With a number of high-profile cases of research malpractice emerging this year, Jonathan Hare asks the US Food and Drug Administration what contract research organisations can do to protect themselves.